Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Lymphoid 1

Conditions

Oligodendroglioma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 8X-Rays 7Specimen Handling 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 5ulixertinib 3trametinib 3palbociclib 3larotrectinib 3erdafitinib 3Temozolomide 3tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ensartinib 2dabrafenib 2Vemurafenib 2Topotecan 2Paclitaxel 2Nivolumab 2Lomustine 2LY3023414 2Gemcitabine 2Filgrastim 2varlilumab 1trastuzumab biosimilar HLX02 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Eflornithine × Lymphoid × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡